This synthetic lethal interaction forms the basis for the clinical efficacy of PARPi, which are used for the treatment of metastatic castration-resistant PCa in patients with mutations in BRCA1 and BRCA2. The gene discussed is BRCA1; the disease is posterior cortical atrophy.